Belite Bio, Inc Reports Higher Losses in Q3
Third Quarter Loss: Belite Bio, Inc reported a loss of -$21.69 million for the third quarter, significantly higher than the -$8.68 million loss from the previous year.
Earnings Per Share: The company's earnings per share (EPS) for the quarter was -$0.65, compared to -$0.28 in the same quarter last year.
Trade with 70% Backtested Accuracy
Analyst Views on BLTE
About BLTE
About the author
Belite Bio Completes Enrollment in DRAGON II Trial for Stargardt Disease
- Trial Enrollment Completion: Belite Bio has completed enrollment of 60 subjects in its DRAGON II clinical trial, including 15 Japanese participants, marking a significant milestone in the treatment of Stargardt disease.
- NDA Filing Plans: The company plans to file a New Drug Application (NDA) with the FDA in the first half of 2026, paving the way for the market introduction of tinlarebant and enhancing its influence in the rare eye disease sector.
- Efficacy Validation: Tinlarebant achieved a 36% reduction in lesion growth in the pivotal Phase 3 DRAGON trial, becoming the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, thereby strengthening its competitive position in the market.
- Multiple Designations Granted: Tinlarebant has received Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations in the U.S., as well as Orphan Drug Designation in the U.S., Europe, and Japan, highlighting its global market potential and the company's commitment to this drug.
Latest Wall Street Ratings Overview
- Dutch Bros Rating: Citi initiates coverage of Dutch Bros (BROS) with a Buy rating, citing its proven portability across the U.S. and a fast-growing marketing budget that is expected to drive sales growth over the next 12-24 months, indicating strong growth potential.
- Tesla Neutral Rating: Goldman Sachs reiterates a Neutral rating on Tesla, expressing concerns that increasing competition in the self-driving sector may limit profit growth, although they remain optimistic about the long-term prospects of its full self-driving and robotaxi operations.
- Apple Price Target Increase: JPMorgan raises its price target for Apple (AAPL) from $305 to $315 ahead of earnings, anticipating a positive setup for the stock as it approaches a key iPhone product cycle, which could enhance its performance.
- Meta Upgrade: Rothschild & Co Redburn upgrades Meta from Neutral to Buy, arguing that its potential in AI is not fully appreciated, raising the price target from $740 to $900, making it an opportune time for investors to build positions.
Wall Street Analysts Adjust Ratings on Key Stocks
- Chime Financial Rating: Rothschild & Co analyst Harry Bartlett initiated coverage on Chime Financial Inc (NASDAQ:CHYM) with a Neutral rating and a price target of $29, while the stock closed at $26.46 on Friday, indicating a cautious market outlook.
- AAR Corp Rating: Goldman Sachs analyst Noah Poponak initiated coverage on AAR Corp (NYSE:AIR) with a Neutral rating and a price target of $121, with shares closing at $105.66, reflecting a conservative expectation for the company's future growth.
- Belite Bio Rating: B of A Securities analyst Tazeen Ahmad initiated coverage on Belite Bio Inc (NASDAQ:BLTE) with a Buy rating and a price target of $195, while the stock closed at $164.58, suggesting an optimistic view on its potential growth.
- Compass Inc Rating: JP Morgan analyst Dae Lee initiated coverage on Compass Inc (NYSE:COMP) with an Overweight rating and a price target of $15, with shares currently at $13.33, indicating a positive outlook for its future performance.
Morgan Stanley Initiates Belite Bio at Overweight with $191 Price Target
- Initiation of Coverage: Morgan Stanley initiates coverage of Belite Bio with an Overweight rating and a price target of $191, reflecting confidence in the company's future growth potential.
- Market Positioning: Belite Bio holds a first-mover advantage in the rare and genetic disease sectors, which is expected to enhance its market share in the biotech industry and bolster investor confidence.
- Growth Potential: With ongoing advancements in clinical trials and product development, Belite Bio is poised for significant revenue growth, attracting increased investor interest.
- Industry Outlook: In the context of a highly competitive biotech landscape, Belite Bio's innovation capabilities and market positioning will provide a strategic advantage in future financing and partnerships.
The $100 Club - Did You Get in Early on the Triple-Digit Surge of ABVX, NUTX, BLTE…?
ABIVAX Société Anonyme: The biotechnology company reached the $100 mark on October 30, 2025, driven by its lead drug candidate, Obefazimod, which is in a pivotal phase III trial for ulcerative colitis. The stock rose from $7.83 in July 2025 to an all-time high of $138.49 in December 2025.
Nutex Health Inc.: This healthcare services company crossed the $100 threshold on April 9, 2025, reflecting significant revenue growth and profitability, with total revenue of $723.6 million for the first nine months of 2025. The stock increased from $33.56 in November 2024 to a peak of $193 in December 2025.
Cidara Therapeutics Inc.: Cidara reached the $100 milestone on October 1, 2025, following its agreement to be acquired by Merck for $221.50 per share. The stock price rose from $18.98 in November 2024, highlighting its growth potential in preventive influenza therapy.
Palvella Therapeutics Inc.: The company, focused on rare diseases, hit the $100 mark on November 24, 2025, after announcing positive results from its phase 2 study. The stock climbed from $25 in March 2025 to a peak of $112 in December 2025, reflecting investor confidence in its ongoing trials.
Belite Bio, Inc - Price Target for Depositary Receipt (BLTE) Raised by 62.05% to 188.02
Revised Price Target: The average one-year price target for Belite Bio, Inc. has been increased to $188.02 per share, reflecting a 62.05% rise from the previous estimate of $116.02.
Analyst Range: Current analyst targets for Belite Bio range from a low of $141.40 to a high of $210.00 per share, indicating a 24.29% increase from the last reported closing price of $151.27.
Fund Sentiment: There has been a significant increase in institutional interest, with 45 funds reporting positions in Belite Bio, a 50% rise in the last quarter, and total shares owned by institutions increasing by 2,316.22% to 2,304K shares.
Major Shareholders: Key institutional shareholders include Ra Capital Management with 875K shares, Rtw Investments and Vestal Point Capital each with 312K shares, and Soleus Capital Management with 210K shares.
Belite Bio Completes Enrollment in DRAGON II Trial for Stargardt Disease
- Trial Enrollment Completion: Belite Bio has completed enrollment of 60 subjects in its DRAGON II clinical trial, including 15 Japanese participants, marking a significant milestone in the treatment of Stargardt disease.
- NDA Filing Plans: The company plans to file a New Drug Application (NDA) with the FDA in the first half of 2026, paving the way for the market introduction of tinlarebant and enhancing its influence in the rare eye disease sector.
- Efficacy Validation: Tinlarebant achieved a 36% reduction in lesion growth in the pivotal Phase 3 DRAGON trial, becoming the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, thereby strengthening its competitive position in the market.
- Multiple Designations Granted: Tinlarebant has received Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations in the U.S., as well as Orphan Drug Designation in the U.S., Europe, and Japan, highlighting its global market potential and the company's commitment to this drug.
Latest Wall Street Ratings Overview
- Dutch Bros Rating: Citi initiates coverage of Dutch Bros (BROS) with a Buy rating, citing its proven portability across the U.S. and a fast-growing marketing budget that is expected to drive sales growth over the next 12-24 months, indicating strong growth potential.
- Tesla Neutral Rating: Goldman Sachs reiterates a Neutral rating on Tesla, expressing concerns that increasing competition in the self-driving sector may limit profit growth, although they remain optimistic about the long-term prospects of its full self-driving and robotaxi operations.
- Apple Price Target Increase: JPMorgan raises its price target for Apple (AAPL) from $305 to $315 ahead of earnings, anticipating a positive setup for the stock as it approaches a key iPhone product cycle, which could enhance its performance.
- Meta Upgrade: Rothschild & Co Redburn upgrades Meta from Neutral to Buy, arguing that its potential in AI is not fully appreciated, raising the price target from $740 to $900, making it an opportune time for investors to build positions.
Wall Street Analysts Adjust Ratings on Key Stocks
- Chime Financial Rating: Rothschild & Co analyst Harry Bartlett initiated coverage on Chime Financial Inc (NASDAQ:CHYM) with a Neutral rating and a price target of $29, while the stock closed at $26.46 on Friday, indicating a cautious market outlook.
- AAR Corp Rating: Goldman Sachs analyst Noah Poponak initiated coverage on AAR Corp (NYSE:AIR) with a Neutral rating and a price target of $121, with shares closing at $105.66, reflecting a conservative expectation for the company's future growth.
- Belite Bio Rating: B of A Securities analyst Tazeen Ahmad initiated coverage on Belite Bio Inc (NASDAQ:BLTE) with a Buy rating and a price target of $195, while the stock closed at $164.58, suggesting an optimistic view on its potential growth.
- Compass Inc Rating: JP Morgan analyst Dae Lee initiated coverage on Compass Inc (NYSE:COMP) with an Overweight rating and a price target of $15, with shares currently at $13.33, indicating a positive outlook for its future performance.
Morgan Stanley Initiates Belite Bio at Overweight with $191 Price Target
- Initiation of Coverage: Morgan Stanley initiates coverage of Belite Bio with an Overweight rating and a price target of $191, reflecting confidence in the company's future growth potential.
- Market Positioning: Belite Bio holds a first-mover advantage in the rare and genetic disease sectors, which is expected to enhance its market share in the biotech industry and bolster investor confidence.
- Growth Potential: With ongoing advancements in clinical trials and product development, Belite Bio is poised for significant revenue growth, attracting increased investor interest.
- Industry Outlook: In the context of a highly competitive biotech landscape, Belite Bio's innovation capabilities and market positioning will provide a strategic advantage in future financing and partnerships.
The $100 Club - Did You Get in Early on the Triple-Digit Surge of ABVX, NUTX, BLTE…?
ABIVAX Société Anonyme: The biotechnology company reached the $100 mark on October 30, 2025, driven by its lead drug candidate, Obefazimod, which is in a pivotal phase III trial for ulcerative colitis. The stock rose from $7.83 in July 2025 to an all-time high of $138.49 in December 2025.
Nutex Health Inc.: This healthcare services company crossed the $100 threshold on April 9, 2025, reflecting significant revenue growth and profitability, with total revenue of $723.6 million for the first nine months of 2025. The stock increased from $33.56 in November 2024 to a peak of $193 in December 2025.
Cidara Therapeutics Inc.: Cidara reached the $100 milestone on October 1, 2025, following its agreement to be acquired by Merck for $221.50 per share. The stock price rose from $18.98 in November 2024, highlighting its growth potential in preventive influenza therapy.
Palvella Therapeutics Inc.: The company, focused on rare diseases, hit the $100 mark on November 24, 2025, after announcing positive results from its phase 2 study. The stock climbed from $25 in March 2025 to a peak of $112 in December 2025, reflecting investor confidence in its ongoing trials.
Belite Bio, Inc - Price Target for Depositary Receipt (BLTE) Raised by 62.05% to 188.02
Revised Price Target: The average one-year price target for Belite Bio, Inc. has been increased to $188.02 per share, reflecting a 62.05% rise from the previous estimate of $116.02.
Analyst Range: Current analyst targets for Belite Bio range from a low of $141.40 to a high of $210.00 per share, indicating a 24.29% increase from the last reported closing price of $151.27.
Fund Sentiment: There has been a significant increase in institutional interest, with 45 funds reporting positions in Belite Bio, a 50% rise in the last quarter, and total shares owned by institutions increasing by 2,316.22% to 2,304K shares.
Major Shareholders: Key institutional shareholders include Ra Capital Management with 875K shares, Rtw Investments and Vestal Point Capital each with 312K shares, and Soleus Capital Management with 210K shares.
